Cenix BioScience is the first Contract Research Organization specialized in combining advanced applications of RNA interference (RNAi) gene silencing with high content phenotyping to enhance and accelerate the discovery and pre-clinical development of novel therapeutics.
Now in its 9th year, Cenix has built-up a solid track record, successfully advancing therapeutic programs for numerous major industry and academic partners by addressing the specific needs of each through fully-customized, cutting-edge research offerings covering a wide range of disease fields.
The well-established core capabilities in high throughput RNAi and multi-parametric microscopy assays have yielded optimized protocols in a broad and ever-growing collection of cultured mammalian cells, and are now complemented by microRNA-focused experimentation and in vivo applications of synthetic siRNAs.
As such, Cenix is a mature, reliable, and fully-proven industrial research partner, applying the highest of scientific best practices and offering a breadth and depth of expertise second to none worldwide.
|Name:Christophe J Echeverri|